drugset

drugset / Trial / NCT00054834

Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma

NCT00054834 ↗

Phase 1 Terminated 27 enrolled Gilead Sciences

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this trial is to determine the safety of 90Y-hLL2 at different dose levels in the treatment of Non-Hodgkin's lymphoma.

Timeline

Start: 2003-03
Primary completion: —
Completion: —

Outcome

Outcome not reported

Stopped (Enrollment): “lack of accrual”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Epratuzumab	Monoclonal antibody	—	—

Indications